WATERTOWN, Mass., May 21, 2025 - Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company, has announced a definitive merger agreement with Sanofi $(SNY)$. Under the terms of the agreement, Sanofi will acquire all outstanding common shares of Vigil for $8.00 per share in cash, amounting to an equity value of approximately $470 million. Additionally, Vigil's shareholders will receive a non-tradeable contingent value right $(CVR)$ entitling them to an additional $2.00 per share in cash, contingent on the first commercial sale of VG-3927. The acquisition is anticipated to bolster Sanofi's neurology focus, particularly in advancing the TREM2 agonist program, including VG-3927, a Phase 2-ready candidate for Alzheimer's treatment. The companies expect the transaction to close in the third quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.